Literature DB >> 11023521

Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation.

M E El-Sabban1, R Nasr, G Dbaibo, O Hermine, N Abboushi, F Quignon, J C Ameisen, F Bex, H de Thé, A Bazarbachi.   

Abstract

Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature activated T cells resistant to conventional chemotherapy. The viral transactivator protein Tax plays a critical role in HTLV-I-induced transformation and apoptosis resistance by inducing I kappa B-alpha degradation, resulting in the activation of the NF-kappa Bpathway. In these HTLV-I-transformed cells, arsenic trioxide (As) and interferon (IFN)-alpha synergize to induce cell cycle arrest and apoptosis. We demonstrate that cell death induction is only partly dependent upon caspase activation and is not associated with modulation of bcl-2, bax, or p53 expression. However, combined As and IFN induce the degradation of Tax, associated with an up-regulation of I kappa B-alpha resulting in a sharp decrease in RelA DNA binding nuclear factor (NF)-kappa B complexes because of the cytoplasmic retention of RelA. Taken the role of Tax in HTLV-I-induced transformation, its down-regulation probably accounts for cell death induction through inactivation of the NF-kappa B pathway. Such specific targeting of the viral oncoprotein by As-IFN treatment, reminiscent of As targeting of promyelocytic leukemia/retinoic acid receptor-alpha in acute promyelocytic leukemia, provides strong rational for combined As-IFN therapy in ATL patients. (Blood. 2000;96:2849-2855)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023521

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

Review 1.  Treatment of T-cell non-Hodgkin's lymphoma.

Authors:  Andrew M Evens; Ronald B Gartenhaus
Journal:  Curr Treat Options Oncol       Date:  2004-08

Review 2.  Adult T cell leukemia lymphoma.

Authors:  Lee Ratner
Journal:  Front Biosci       Date:  2004-09-01

Review 3.  PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Nucleus       Date:  2014       Impact factor: 4.197

4.  Activation of PERK-ATF4-CHOP pathway as a novel therapeutic approach for efficient elimination of HTLV-1-infected cells.

Authors:  Emi Ikebe; Sahoko Matsuoka; Kenta Tezuka; Madoka Kuramitsu; Kazu Okuma; Makoto Nakashima; Seiichiro Kobayashi; Junya Makiyama; Makoto Yamagishi; Seiichi Oyadomari; Kaoru Uchimaru; Isao Hamaguchi
Journal:  Blood Adv       Date:  2020-05-12

5.  In vitro effects of arsenic trioxide, interferon α and zidovudine in adult T cell leukemia/lymphoma cells.

Authors:  Miho Hachiman; Makoto Yoshimitsu; Chibueze Ezinne; Ayako Kuroki; Tomohiro Kozako; Naomichi Arima
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

Review 6.  Old dog, new trick: Trivalent arsenic as an immunomodulatory drug.

Authors:  Yishan Ye; Béatrice Gaugler; Mohamad Mohty; Florent Malard
Journal:  Br J Pharmacol       Date:  2020-03-12       Impact factor: 8.739

Review 7.  Human T cell lymphotropic virus-associated leukemia/lymphoma.

Authors:  Lee Ratner
Journal:  Curr Opin Oncol       Date:  2005-09       Impact factor: 3.645

8.  NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).

Authors:  Daniella M B Kerbauy; Vladimir Lesnikov; Nissa Abbasi; Sudeshna Seal; Bart Scott; H Joachim Deeg
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

9.  Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1.

Authors:  Megan Brown; Marcia Bellon; Christophe Nicot
Journal:  Blood       Date:  2006-10-31       Impact factor: 22.113

Review 10.  How animal models of leukaemias have already benefited patients.

Authors:  Julien Ablain; Rihab Nasr; Jun Zhu; Ali Bazarbachi; Valérie Lallemand-Breittenbach; Hugues de Thé
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.